文献速递系统性红斑狼疮其他结缔组织病脊柱关节炎

跨性别者中的免疫介导炎症性风湿病:范围综述

Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review.
PubMed 文献 · Semin Arthritis Rheum · 2021-10-28

该范围综述通过系统检索 Medline、Embase 和 Web of Knowledge,收集跨性别者中任何免疫介导炎症性风湿病(IMIRD)的文献。共发现 11 例跨性别女性和 3 例跨性别男性病例,涉及系统性红斑狼疮、皮肤红斑狼疮、系统性硬化症、抗合成酶综合征、类风湿关节炎和强直性脊柱炎,未识别到临床研究,文献质量参差不齐。作者认为病例数虽少但多数发生于跨性别女性,缺乏可靠数据使得难以就激素替代治疗给出推荐。

要点

  • 11 例为新发 IMIRD,3 例在开始激素替代治疗后出现合并症。
  • 2 例跨性别女性和 1 例跨性别男性发生血栓事件。

核心结论

  • 尽管病例数少,多数 IMIRD 病例发生于跨性别女性。
  • 缺乏可靠数据,使得就跨性别 IMIRD 患者的激素替代治疗建立推荐需谨慎。
  • 未来 IMIRD 研究有必要考虑顺性别与跨性别的特殊性。

研究设计与样本

  • 范围综述,通过系统检索 Medline、Embase 和 Web of Knowledge 收集跨性别患者中任何 IMIRD 的出版物。
  • 对报告临床研究的文章进行了半定量质量评价。

主要发现

  • 共 11 例跨性别女性和 3 例跨性别男性病例:系统性红斑狼疮 5 例、皮肤红斑狼疮 2 例、系统性硬化症 4 例、抗合成酶综合征 1 例、类风湿关节炎 1 例、强直性脊柱炎 1 例。
  • 11 例为新发 IMIRD,3 例有 IMIRD 既往史并在开始激素替代治疗后出现合并症。
  • 疾病临床表现多样;2 例跨性别女性和 1 例跨性别男性发生血栓事件;1 例跨性别男性的狼疮皮肤病变在睾酮治疗后改善。
  • 未识别到临床研究;出版物质量参差不齐。

局限性

  • 病例数少。
  • 缺乏可靠数据,使得就跨性别 IMIRD 患者的激素替代治疗建立推荐需谨慎。
  • 未识别到临床研究。
  • 出版物质量参差不齐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In immune-mediated inflammatory rheumatic diseases (IMIRD), there are differences between cis-men and cis-women in epidemiology, clinical feature, therapeutic approach, treatment response, and prognosis. In transgender individuals, information concerning IMIRD is not substantial. The assessment of information concerning rheumatic diseases in transgenders is crucial because transgenders may undergo treatments with potential impacts on IMIRD. We aim to collect and discuss current knowledge on IMIRD in transgender individuals, determine the coverage of the literature, identify the knowledge gaps, and highlight opportunities for future research. METHODS: We did a scoping review of publications collected through a systematic search of transgender patients with any IMIRD. Data sources were Medline, Embase, and Web of Knowledge. Synthesis of results and qualitative review of data information was collected in tables. A semi-quantification of the quality of the articles reporting clinical studies was performed. RESULTS: There were 11 transwoman, and 3 transmen cases of systemic lupus erythematosus (5 cases), skin lupus erythematosus (2), systemic sclerosis (4), anti-synthetase syndrome (1), rheumatoid arthritis (1) and ankylosing spondylitis (1). Eleven were de novo cases and three had prior history of IMIRD and developed a comorbidity after starting hormone replacement therapy. The clinical expression of the disease was variable. Two transwomen and one transman developed thrombotic events. The lupus skin lesions in one transman improved following testosterone treatment. No clinical studies were identified. Quality of publications was disparate. CONCLUSION: Although the number of cases is small, most cases of IMIRD occur in transwomen. The absence of solid data warrants caution in establishing recommendations regarding hormone replacement therapy in transgenders with IMIRD. There is an essential need for the consideration of cisgender and transgender particularities in future research on IMIRD.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Salgado E, Romera-Baurés M, Beltran-Catalan E, et al. Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review. Semin Arthritis Rheum. 2021. PMID: 34872742. doi:10.1016/j.semarthrit.2021.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。